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Background: The altered hemodynamics, and therefore the arterial hypotension is the most prevalent adverse
effect after subarachnoid anesthesia. The objective of the study was to determine the exact role of local anesthetic
selection underlying spinal anesthesia-induced hypotension in the elderly patient. We conducted a descriptive,
observational pilot study to assess the hemodynamic impact of subarachnoid anesthesia with isobaric levobupivacaine
versus hyperbaric bupivacaine for hip fracture surgery.
Description: Hundred twenty ASA status I-IV patients aged 65 and older undergoing hip fracture surgery were enrolled.
The primary objective of our study was to compare hemodynamic effects based on systolic blood pressure (SBP) and
dyastolic blood pressure (DBP) values, heart rate (HR) and hemoglobin (Hb) and respiratory effects based on partial
oxygen saturation (SpO2%) values. The secondary objective was to assess potential adverse events with the use of
levobupivacaine versus bupivacaine. Assessments were performed preoperatively, at 30 minutes into surgery, at
the end of anesthesia and at 48 hours and 6 months after surgery.
Among intraoperative events, the incidence of hypotension was statistically significantly higher (p <0.05) in
group BUPI (38.3%) compared to group LEVO (13.3%). There was a decrease (p <0.05) in systolic blood pressure
(SBP) and diastolic blood pressure (DBP) at 30 minutes intraoperatively (19% in group BUPI versus 17% in group
LEVO). SpO2% increased at 30 minutes after anesthesia onset (1% in group BUPI versus 1.5% in group LEVO).
Heart rate (HR) decreased at 30 minutes after anesthesia onset (5% in group BUPI versus 9% in group L).
Hemoglobin (Hb) decreased from time of operating room (OR) admission to the end of anesthesia (9.3% in
group BUPI versus 12.5% in group LEVO). The incidence of red blood cell (RBC) transfusion was 13.3% in group
BUPI versus 31.7% in group LEVO, this difference was statistically significant. Among postoperative events, the
incidence of congestive heart failure (CHF) was significantly higher in group BUPI (8,3%). At 6 months after
anesthesia, no differences were found.
Conclusions: Given the hemodynamic stability and lower incidence of intraoperative hypotension observed,
levobupivacaine could be the agent of choice for subarachnoid anesthesia in elderly patients.
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Hip fractures are common in the elderly population of de-
veloped countries. Approximately 30,000 hip fractures occur
in Spain every year, at an average age of 80 years [1]. Hos-
pital mortality in Spain due to hip fractures ranges between
4% and 8% [2] and can be as high as 30% at 12 months after
hip fracture surgery [3,4].
Perioperative morbidity and mortality can be influenced
by both the anesthetic agent [5] and the surgical proce-
dures. Pathophysiological changes associated with aging,
significant comorbidities, treatment with multiple medica-
tions and a reduced functional reserve render the elderly
more vulnerable to the pharmacological effects of drugs in
general and particularly to local and general anesthetics
[6]. Racemic bupivacaine is considered the long-acting
local anesthetic of choice in several regional anesthetic
procedures [7-9], especially for subarachnoid administra-
tion. Levobupivacaine is the S-enantiomer of racemic
bupivacaine. Clinical studies have shown that bupivacaine
and levobupivacaine are equally effective [5,10], however,
levobupivacaine has lower affinity for sodium channels in
the heart [11], and therefore it is less frequently associated
with cardiovascular (CV) events.
A recent systematic review [12] suggests that neuraxial
(subarachnoid and epidural) regional techniques reduce
to 1/3 the incidence of postoperative myocardial infarc-
tion; these authors recommend preventing hypotension
associated with spinal blocks, hypoxia and anemia, as
these may lead to the occurrence of perioperative ad-
verse events [13,14].
The primary objective of our study was to compare
hemodynamic effects based on systolic blood pressure
(SBP) and dyastolic blood pressure (DBP) values, heart
rate (HR) and hemoglobin (Hb) and respiratory effects
based on partial oxygen saturation (SpO2%) values.
The secondary objective of the study was to assess
potential adverse events with the use of isobaric levo-
bupivacaine versus hyperbaric bupivacaine, associated
with both the surgical and the anesthetic procedures,
and death.
There is little evidence comparing the use of levobupiva-
caine [10] versus bupivacaine, either in clinical practice
[15,16] or in studies assessing the safety of one versus the
other [17-21]. Assessments were conducted preoperatively,
at 30 minutes after anesthesia, at the end of anesthesia
(when the patient could be transferred to the post surgical
recovery unit), and at 48 hours and 6 months postopera-
tively. The ideal subarachnoid block for management of
aged 65 and older undergoing hip surgery remains elusive,
especially in respect of dosing and local anesthetic selec-
tion. To explore these issues, we compare two differing
local anesthetics (LA) formulations. Comparative evidence
on the effectiveness of the two LA was obtained through a
structured database.Construction and content
This was a descriptive, observational pilot study to assess
the hemodynamic effects of subarachnoid anesthesia
with isobaric levobupivacaine versus hyperbaric bupiva-
caine in 120 ASA status I-IV patients aged 65 and older
undergoing hip fracture surgery at Consorcio Hospital
General Universitario (CHGUV), Valencia, Spain. As-
sessments were conducted preoperatively, at 30 minutes
of the anesthesia, at the end of anesthesia and at 48 hours
and 6 months postoperatively.
Patients were divided into two groups based on the type
of anesthetic solution used: group LEVO included patients
with 0.5% isobaric levobupivacaine (Chirocane™, Abbott)
plus fentanyl 50 μg/mL (solution A), and group BUPI in-
cluded patients with 0.5% hyperbaric bupivacaine (Braun,
Rubí, Spain) plus fentanyl 50 μg/mL (solution B).
A total of 120 patients were included (60 patients in
the isobaric levobupivacaine group and 60 in the hyper-
baric bupivacaine group).
Inclusion criteria were as follows: males and females
aged 65 or older diagnosed with a hip fracture and
treated with intrathecal anesthesia with levobupivacaine
plus fentanyl or bupivacaine plus fentanyl (hyperbaric
bupivacaine and isobaric levobupivacaine dosages ranged
between 5 mg and 15 mg, and the dose range for fen-
tanyl was 10 μg to 20 μg); patients with or without
stable cardiovascular, respiratory, renal and/or endocrine
disease classified as I-IV according to the American
Society of Anesthesiologists (ASA); body weight >40 kg;
height >140 cm; body mass index (BMI) <50 kg/m2.
We excluded those patients who underwent spinal
anesthesia with general anesthesia that required by tech-
nical failure or prolonged surgical time.
Before the study was initiated, approval was obtained
from the Research Commission and the Clinical Research
Ethics Committee at the Department of Health of Valencia,
Hospital General (no. 538, no. 1) and the project was
reviewed by the Spanish Regulatory Drug Agency (AEMPS)
and classified as a ‘post-marketing, non-prospective follow-
up study’, protocol number RHC-LEV-2012-01.
The study was conducted in accordance with the princi-
ples laid out in the Declaration of Helsinki and the applic-
able law and regulations governing personal data protection
and rights and responsibilities regarding information and
documentation in healthcare.
The standard subarachnoid technique was used, with
the patient placed in the lateral position with the af-
fected limb raised or lowered as chosen by the desig-
nated anesthesiologist. After sterilizing the anesthetic
field, local infiltration was performed using 2% lidocaine.
Both solution A or solution B of the anesthetic were ad-
ministered by the anesthesiologist (from the Anesthesiology
department allocated to the operating room (OR) accord-
ing to the hospital’s organizational chart) aseptically in the
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Puncture was performed using the midline or paramedian
approach in intervertebral spaces L2-L3, L3-L4 or L4-L5,
with the bevel in the cephalic or caudal direction. After
confirmation of clear cerebrospinal fluid (CSF) efflux, so-
lution A (n =60) or solution B (n =60) was administered.
The solution was injected with or without prior aspiration
of CSF.
Once the subarachnoid puncture was completed, pa-
tients were placed in the supine position and urinary
catheterization was performed. Patients were moved off
the bed onto the surgical table, where they were posi-
tioned for surgery in the lateral or supine position ac-
cording to the type of fracture and the fixation material
to be implanted.
Data were collected by specially trained personnel from
the patients’ hospital records in the CHGUV archive, con-
secutively and retrospectively between January 2010 and
November 2011. Personal confidential data items for this
database study were processed under government trans-
parency guidance and managed in line with statistics au-
thority guidance on the handling of small numbers to
prevent the identification of individuals. To make sure
personal data were kept confidential, the sample was
anonymized using a double code list. Each patient was
assigned a unique two- or three-digit number (01, 02…,
60…, 120), from 01 to 120.
The following data were collected:
Socio-demographic variables were collected: patient
data, including unique code number (consecutive study
number), gender, age (years), body weight (kg), height
(cm), and BMI (kg/m2); presence of CV, respiratory,
neurological, hepatic/renal or endocrine/metabolic disease,
history of anti-platelet or anticoagulant agent use prior to
surgery; premedication (midazolam, and/or fentanyl, and/
or ketamine); type of hip fracture and hospital stay in days.
Before initiation of surgery, anesthesiologists checked
sensory and motor blocks. The level of sensory block
was assessed using the pinprick test (1 = hypoalgesia;
2 = analgesia; 3 = analgesia plus hypoesthesia; and 4 =
anesthesia) using a 22 G blunt hypodermal needle.
The level of motor block was assessed using the modi-
fied Bromage scale (0 = no motor block, able to flex
hips, knees and ankles; 1 = just able to flex knees, un-
able to extend legs; 2 = able to move ankles, unable to
flex knees; 3 = unable to flex ankles, knees or hips,
complete motor block).
Anesthetic and surgical technique variables were col-
lected, such as level of puncture (L2-L3, L3-L4, or L4-L5);
volume of local anesthetic (mL) and fentanyl (μg) adminis-
tered, and type of surgical implant; and surgical times and
anesthetic times in minutes.
Non invasive hemodynamic monitoring placing six
electrocardiographic leads, heart rate (HR) measured inbeats per minute (bpm), the oxygen saturation in %
expressed through a pulse oximeter placed on the index
finger (SpO2%) and blood pressures systolic and diastolic
measured in mmHg, haemoglobin in g/dL.
Information was collected on potential adverse events
during the intraoperative period. Hypotension and brady-
cardia were defined as a reduction from baseline by >20%
in mean arterial pressure (MAP) and HR, respectively.
Adverse events included CV and respiratory events, such
as venous gas embolism, deep vein thrombosis (DVT),
acute myocardial infarction (AMI), stroke, congestive
heart failure (CHF), pneumonia or death, and other events
such as acute renal failure (ARF) and vomiting. Events as-
sociated with the surgical procedure included red blood
cells transfusion (RBC), plasma transfusion (PT), nerve in-
jury (NI), femur fracture; (FF) events associated with the
anesthetic procedure included paresthesia, bloody punc-
ture, and others.
The assessment performed at 48 hours postoperatively in-
cluded the following adverse events: DVT, AMI, stroke,
CHF, pneumonia and death; and others such as ARF, urinary
tract infection, and vomiting. Events associated with the sur-
gical procedure included RBC transfusion (anesthesiologist’ s
choice), plasma transfusion, neurological deficits and sur-
gical site infection.
Potential adverse events occurring at 6 months postop-
eratively included CV/respiratory events, such as exacer-
bation of CV disease, exacerbation of respiratory disease,
exacerbation of kidney disease, and death. The potential
adverse events associated with the surgical procedure
were neurological deficits and those associated with
the anesthetic procedure were metameric dysesthesia,
low back pain, and others.
With a sample size of 120 patients (60 in each group),
the study had 85% statistical power to detect minimal
differences between groups of 20 mmHg in SBP and
DBP, 20 bpm in HR, 5 g Hb, and 2 percentage points in
partial oxygen saturation.
A specific case report form was developed for this
study and the data were transferred to the SPSS 15.0
software for Windows. The information in the database
was checked for quality to avoid inconsistencies and du-
plicated or inaccurate data.
Descriptive statistics were used and the arithmetic
mean and the standard deviation were determined for
each variable. Comparisons between groups were per-
formed using the Friedman test. The Mann-Whitney test
was used to assess the groups for homogeneity. Pearson’s
chi-squared test and Fisher’s exact test were used to as-
sess associations between qualitative variables. Signifi-
cance was set at p <0.05.
Both patient groups had similar socio-demographic
characteristics and comorbidities. The most frequent
comorbidities were CV and respiratory diseases in both
Table 1 Characteristics of patients at baseline
A. Socio-demographic variables expressed as mean (SD)
N Minimum Maximum Mean Standard
deviation
AGE (years) 119 60 100 84 7.15
WEIGHT (kg) 103 40 120 65 13.02
SIZE (cm) 72 140 181 160 7.92
BMI (kg/m2) 71 12 31 20 3.63
B. Socio-demographic variables expressed in percentage (%)
Frequency Percentage
VALID Man 25 21
Woman 95 80
Total 120 100
C. Variables related to the main objective
BUPI (N =60) LEVO (N =60)
Mean Standard deviation Minimum Maximum Mean Standard
deviation
Minimum Maximum
AGE (years) 83 7.24 60 96 85 6.92 66 100
WEIGHT (kg) 66 14.78 44 120 64 11.32 40 90
SIZE (cm) 159 7.83 140 181 160 8.08 140 175
BMI (kg/m2) 20 3.57 14 27 20 3.73 12 31
SBP (mmHg) 143 19.50 110 190 156 28.33 100 230
DBP (mmHg) 82 13.74 60 120 79 20.04 50 175
HR ((bpm) 85 17.84 60 150 89 21.27 50 170
Hb (g/dl) 12 1.62 8 16 12 1.61 8 18
SpO2 (%) 96 3.66 85 100 95 2.75 88 99
D. Clinical variables
BUPI (N =60) LEVO (N =60)
N % N %
GENDER Man 11 18% 14 23%
Woman 49 82% 46 77%
BASIC PATHOLOGY RESPIRATORY 13 22% 8 13%
VASCULAR 44 73% 39 65%
NEUROLOGICAL 23 38% 24 40%
CARDIAC 21 35% 25 42%
HEPATIC/RENAL 7 12% 10 17%
ENDOCRINE/METABOLIC 31 52% 30 50%
HISTORY OF ANTI-PLATELET
OR ANTICOAGULANT AGENT
25 42% 26 43%
USE PRIOR TO SURGERY: PREMEDICATION 40 67% 51 85%
TYPE OF HIP
FRACTURE
Head neck fracture 0 0% 0 0%
Subcapital fracture 21 35% 15 25%
Transcervical fracture 0 0% 2 3%
Basicervical fracture 6 10% 8 13%
Pertrochanteric fracture 28 47% 30 50%
Subtrochanteric fracture 4 7% 5 8%
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Table 1 Characteristics of patients at baseline (Continued)
DURING
SURGERY
OSTEOSYNTHESIS
IMPLANT TYPE
Osteosynthesis (OS) 4 7% 2 3%
Partial hip prosthesis (PHP) 17 28% 17 28%
Total hip prosthesis (THP) 4 7% 2 3%
Arthroplasty (ARP) 0 0% 0 0%
Dynamic Hip System plates
(DHS)
28 47% 25 42%
GAMMA plates (GAMMA) 8 13% 8 13%
Condylar Nail-Plate s (DCS) 0 0% 0 0%
Others (Oth) 0 0% 5 8%
SPINAL LEVEL L2-L3 13 22% 10 17%
L3-L4 35 58% 31 52%
L4-L5 12 20% 19 32%
ANESTHESIC VOLUME 1 ml 4 7% 18 30%
1.2 ml 10 17% 36 60%
1.3-1.5 ml 32 53% 5 8%
>1.5 ml 14 23% 1 2%
DOSE OF FENTANYL 5 1 1.7% 0 0%
10 52 87% 56 93%
15 3 5% 0 0%
BUPI = hyperbaric bupivacaine; LEVO = isobaric levobupivacaine; BMI = body mass index; SBP = systolic blood pressure, DBP = diastolic blood pressure; HR = heart
rate; Hb = haemoglobin; SpO2 = partial oxygen saturation; Osteosynthesis (OS); Partial Hip Prosthesis (PHP); Total Hip Prosthesis (THP); Arthroplasty (ARP).
Dynamic Hip System plates (DHS); GAMMA plates (GAMMA); Condylar Nail-Plates (DCS); Others (Oth).
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for sedation in 76% of all patients (Table 1).
The levels of sensory and motor block were not provided
in the study because they were generally not recorded in
the chart of anesthesia.
In both groups there is a percentage decrease in SBP
(mean preoperative SBP 156 ± 28 mmHg for LEVO and
143 ± 19 mmHg for BUPI) and DBP (mean preoperative
DBP 79 ± 20 mmHg for LEVO and 82 ± 14 mmHg for
BUPI) after 30 minutes of anesthesia (p <0.05), LEVO
17% and 19% with BUPI. In general, no significant vari-
ation appears after the first half hour, however, the BUPI,
slightly increases the SBP (mean intraoperative SBP 129 ±
20 mmHg for LEVO and 115 ± 16 mmHg for BUPI and
mean SBP at the end of anesthesia 125 ± 20 mmHg for
LEVO and 120 ± 15 mmHg for BUPI) (Figure 1).
SpO2 values at 30 minutes after induction (95% BUPI,
96% LEVO) were significantly increased in percent (p <0.05)
as compared to preoperative values (96% BUPI, 95% LEVO).
In both groups SpO2 increased at 30 minutes after
anesthesia of 1% with BUPI and 1.5% with LEVO.
There were no differences in these values assessed at
30 minutes after induction of anesthesia versus at the
end of anesthesia (97% BUPI, 97% LEVO) (Figure 2).
In both groups there was a percentage decrease of HR
at 30 minutes of anesthesia (81 bpm BUPI, 81 bpm
LEVO), 5% with BUPI and 9% with LEVO (preoperativevalues 85 bpm BUPI, 89 bpm LEVO). In general, no sig-
nificant variation appears after 30 minutes of anesthesia
(Figure 3).
A significant percentage decrease in Hb occurred with
both anesthetics from preoperative values (12 g/dL BUPI, 12
g/dL LEVO) to the end of surgery (11 g/dL BUPI, 10 g/dL
LEVO). The mean percentage decrease was 9% with bupiva-
caine and 12% with levobupivacaine; however, there were no
significant differences between both values (Figure 4).
We had not recorded either the eventual use of vaso-
pressors or intraoperative fluid therapy because they
were not properly recorded in the charts of anesthesia.
Adverse events assessed intraoperatively, at 48 hours and
at 6 months postoperatively are shown in Table 2. Among
intraoperative events, the incidence of hypotension was
significantly higher (p <0.05) in group BUPI (38%) com-
pared to group LEVO (13%). The incidence of RBC trans-
fusion was 13% in group BUPI versus 32% in group LEVO.
These differences were statistically significant. Among
postoperative events, the rate of CHF was significantly
higher in group BUPI (8%) and was not recorded in
the group LEVO. At 6 months after anesthesia, no dif-
ferences were found in adverse events according to the
local anesthetic agent used.
Puncture was performed at L3-L4 in 55% of all patients
(58% in group BUPI versus 52% in group LEVO). Sub-
arachnoid block was undertaken using a mean local
Figure 1 Effect of bupivacaine (BUPI) (A) and of levobupivacaine (LEVO) (B) on systolic blood pressure (SBP) and diastolic blood
pressure (DBP) to the entry in OR admission, at 30 minutes of anesthesia and end of anesthesia. Significant difference in SBP change at
30 minutes after anesthesia onset (p <0.05); BUPI = hyperbaric bupivacaine; LEVO = isobaric levobupivacaine; OR, operating room; SBP = systolic
blood pressure; DBP = diastolic blood pressure.
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mean dose of 11 ± 3 μg fentanyl (range 5-20). A higher
volume of bupivacaine was used (1.4 mL) compared to
levobupivacaine (1.2 mL). In group BUPI, 53% of patients
received 1.3 to 1.5 mL, whereas 60% of patients in group
LEVO received 1.2 mL. Significant differences were found
in the volume of the anesthetic solution but not in the
dose of fentanyl: 90% of patients (n =108) received 10 μg
fentanyl. In group BUPI, patients received a mean dose of
11 ± 2.8 μg fentanyl and group LEVO, patients received a
mean dose of 11 ± 2.5 μg fentanyl.
Surgical and anesthetic times were also assessed. Mean
surgical time was 58 ± 28 minutes (range 195-25): 61 ±
27 minutes in group BUPI (range 195-30) versus 55 ± 28
minutes in group LEVO (range 160-25). Mean anesthetic
time was 92 ± 28 minutes (range 225-45): 97 ± 32 in group
BUPI (range 225-45) versus 88 ± 24 in group LEVO (range
150-45).Mean hospital stay was 8 days (range 20-3) with no
significant differences between the groups.
Utility and discussion
The relative contribution of anaesthesia to outcome after
hip fracture repair remains uncertain, but experience
across medicine suggests that better outcomes are asso-
ciated with standardisation of practice. A key objective of
the current database has been to present our practice – so
as to develop a consensus regarding best practice in
hemodynamic impact of subarachnoid LA administration
in elderly population with hip fracture. These results
will help individual anaesthetists and departments of
anaesthesia to improve the management of this sensible
population.
Research in the complex, heterogeneous hip fracture
population is difficult, making it difficult to formulate
strong conclusions. The National Hip Fracture Database
LEVOBUPI
100
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96
94
92
90
88
86
11 16
25
18
94
110
98
18
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1218
11
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Anesthesia
Oxygen saturation: post
Oxygen saturation: intra
Oxygen saturation: pre
Figure 2 SpO2 values according to anesthetic time point and anesthetic use (BUPI or LEVO). BUPI = hyperbaric bupivacaine; LEVO = isobaric
levobupivacaine; Oxygen saturation: pre = partial oxygen saturation at operating room (OR) admission; Oxygen saturation: intra = partial oxygen
saturation at 30 minutes after onset of anesthesia; Oxygen saturation: post = partial oxygen saturation at the end of anesthesia; SpO2% = partial
oxygen saturation. ★p <0.05 from preoperative values; 0 = atypical value (the numbers next to atypical values refer to case number in the
database and not the value of the SpO2).
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2007, it has collected data on over 200 000 hip fracture
patients, and currently collects data from 95% of all hip
fracture patients presenting to each of the 188 hospitals
in England, Wales and Northern Ireland that are eligible
for inclusion. However, there are some striking findings,
most notably the high prevalence of intraoperative
hypotension, the limited use of nerve blockade in
addition to spinal and/or general anaesthesia and the
wide inter-hospital variation in type of anaesthesia
administered.
White et al in their database [23] analysed 65 535 pa-
tient record sets to determine differences in outcome.
Type of anaesthesia was recorded in 59 191 (90%) patients.
There was no significant difference in either cumulative
five-day (2.8% vs 2.8%, p =0.991) or 30-day (7.0% vs
7.5%, p =0.053) mortality between 30 130 patients receiv-
ing general anaesthesia and 22 999 patients receiving
spinal anaesthesia. If these data are accurate, researchshould focus on how to make both types of anaesthesia
safer, and therefore future research should focus on dif-
ferences between general and spinal anaesthesia. These
could include more anaesthesia-sensitive outcomes,
such as hypotension, pain, postoperative confusion, re-
spiratory infection and mobilisation.
In this sense the main utility of our paper is to assess
the hemodynamic impact of levobupivacaine and hyper-
baric bupivacaine in patients with 65 or more years with
hip fracture during surgery, at 48 hours and at 6 months
after surgery. During the intra-operative period was de-
tected a percentage decrease in SBP and DBP after 30
minutes of anesthesia in both groups. This could be ex-
plained partly by the baricity of the local anesthetic.
Hyperbaric bupivacaine is characterized by earlier onset
of action, greater cephalic distribution and greater initial
reduction of SBP and DBP. Furthermore, the dosages of
the local anesthetics could have influenced the results as
well, as the volume of bupivacaine injected was higher
Anesthesia
LEVOBUPI
–
2,00
1,00
0,00
-1,00
-2,00
-3,00
-4,00
19
97
11
88
92
117
89
107
119
Global Hb change: end of anesthesia preop value
Figure 4 Hemoglobin values according to local anesthetic (BUPI or LEVO) at end of anesthesia versus OR admission. BUPI = hyperbaric
bupivacaine; LEVO = isobaric levobupivacaine, OR, operating room; 0 = atypical value (the numbers next to atypical values refer to case number in
the database and not the value of the Hb).
Change from preoperative value 
to 30 minutes after onset
Change from 30 minutes after onset
to end of anesthesia
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Figure 3 Heart rate (HR) values according to anesthesia time point. BUPI = hyperbaric bupivacaine; LEVO= isobaric levobupivacaine; 0 = atypical
value (the numbers next to atypical values refer to case number in the database and not the value of the HR); ★extreme value.
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Table 2 Adverse events with bupivacaine and levobupivacaine
A. Intraoperative adverse events
Total (N =120) BUPI (N =60) LEVO (N =60)
N % N % N %
Stroke 1 1% 0 0% 1 2%
Hypotension 31 26% 3 38%★ 8 13%
Vomiting 1 1% 1 2% 0 0%
RBC transfusion 27 22% 8 13% 19 32%★
B. Adverse events at 48 hours after surgery
Total (N =120) BUPI (N =60) LEVO (N =60)
N % N %
Pneumonia 1 1% 1 2% 0 0%
CHF 5 4% 5 8%★ 0 0%
RF 4 3% 2 3% 2 3%
RBC
Transfusion 34 28% 16 26% 18 30%
C. Adverse events at 6 months postoperatively
Total (N =120) BUPI (N =60) LEVO (N =60)
N % N % N %
Exacerbation of kidney disease 3 2% 2 3 1 2%
Death 8 7% 5 8% 3 5%
Exacerbation of cardio-vascular disease 5 4% 4 7% 1 2%
Exacerbation of pulmonary disease 4 3% 2 3% 2 3%
BUPI = hyperbaric bupivacaine; LEVO = isobaric levobupivacaine; RBC = red blood cells; ARF = acute renal failure; B = hyperbaric bupivacaine; CHF = congestive
heart failure; RF = renal failure; ★Statistically significant difference (p <0.05).
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which could account for the differences seen at the end
of anesthesia.
In these series, among the intraoperative adverse events
collected, there was a three times higher incidence of
hypotension in group BUPI and two and a half higher in-
cidence of RBC transfusion in group LEVO. In the group
treated with bupivacaine, we used more local anesthetic
and its onset of action was earlier. This could have favored
more hypotension events. As for the transfusions of blood
products, Wood et al [19] observed a very slight change in
Hb concentrations in patients who received low dosages
of local subarachnoid anesthetics compared to higher dos-
ages. These authors suggest that this could be due to less
hemodilution as a result of less fluid administration in the
group treated with lower dosages. This avoided the use of
vasopressors and reduced the administration of intraven-
ous fluid. It is possible that the trend to reduce the admin-
istration of fluid may have favored hemoconcentration
and therefore hematological loss would have been greater.
However, we have not recorded either the eventual use of
vasopressors or intraoperative fluid therapy.
At 48 hours after surgery, the incidence rate of heart
failure was 8.3% in group BUPI versus no cases in group
LEVO. This was possibly related to the therapeuticprocedures to counteract hypotension —such as intra-
venous administration of fluid and vasopressor drugs—
and to anemia, leading to interstitial edema and acute
pulmonary edema.
At 6 months postoperatively, the number of adverse
events was higher in group BUPI than in group LEVO,
but the difference was not statistically significant. Death
occurred in 6.7% of all patients who underwent surgery,
regardless of gender (8.3% in group BUPI versus 5% in
group LEVO). These events could be related to the
higher prevalence rates of intraoperative hypotension in
group BUPI, CHF at 48 hours postoperatively and pos-
sibly secondary ischemia involving target organs such as
the heart and the kidneys.
In elderly patients with chronic coexistent diseases, epi-
sodes of hypotension and operative bleeding may promote
the occurrence of intra- and post-operative adverse events,
particularly ischemia and anemia [5,14,20], which involve
a high risk for secondary complications such as AMI,
acute and/or chronic renal failure, or death, among
others.
Several authors have reported low prevalence rates of
intraoperative hypotension with low dosages of sub-
arachnoid bupivacaine and levobupivacaine for hip frac-
ture surgery [10,20]. The mechanism of this undesirable
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cephalic diffusion of the local anesthetic and the conse-
quent lower reduction of systemic vascular resistances.
Levobupivacaine has been shown to result in greater vaso-
constriction at all concentrations compared to racemic
bupivacaine [24,25]. That would explain the lower inci-
dence of hemodynamic effects compared to bupivacaine,
which causes vasodilation (leading to arterial hypotension
and bradycardia). The prevalence of non-failed subarach-
noid block with lower doses of up to 4 mg of anesthetic
has been reported in the literature [26] and may be a con-
sequence of the pathophysiological changes occurring
with aging and the concurrent diseases in these patients.
Studies can be found in the literature for urological
and lower abdominal surgery comparing these two local
anesthetics using the subarachnoid approach. However,
there are few specific studies in hip surgery, particularly
in hip fracture surgery [27,28].
Wood et al [19] followed a series of 1,131 patients
who underwent proximal femur fracture surgery and
were treated with 0.5% hyperbaric bupivacaine, observ-
ing lower prevalence rates of intraoperative hypotension
in the group treated with <1.5 mL. Fattorini et al [15]
compared, in a series of only 60 patients undergoing
major orthopedic surgery, 3 mL of 0.5% levobupivacaine
versus 3 mL of 0.5% bupivacaine for major lower limb
surgery and observed a slight decrease in MAP and HR,
but no significant differences between the groups.
There were a number of limitations to our study.
Collection of data in the anesthetic sheet was not ac-
curate, especially because SBP and DBP values were
not collected invasively and because readings of these
values could have been influenced subjectively by the
investigators. Preoperative Hb values were collected
for all cases; however, intra- and postoperative Hb values
were missing for some.
We agree with Benes et al that it is essential to ascer-
tain the patient’s blood volume status to determine the
appropriate strategy for hemodynamic management [29].
A number of ‘static’ markers had been typically used
(central venous pressure (CVP), pulmonary capillary wedge
pressure (PCWP)), but their efficacy has been questioned
in recent studies [29,30]. A novel approach, based on some
physiological phenomena or new technologies, is now tak-
ing hold, supported by new insights in physiology and
technology. These are the so-called ‘dynamic’ markers,
which can be assessed using electronic devices (such as
FloTrac/Vigileo).
Conclusions
We conclude from our study that subarachnoid administra-
tion of low-dose 0.5% levobupivacaine (mean volume of 1.2
mL) plus fentanyl in elderly patients undergoing hip fracture
surgery was as safe as the administration of low-dosehyperbaric bupivacaine (mean volume ranging between 1.3
mL and 1.5 mL) plus fentanyl. Our results, especially regard-
ing intra- and postoperative events, suggest that subarach-
noid low-dose isobaric levobupivacaine was safer and should
be used instead of hyperbaric bupivacaine in elderly patients
undergoing surgical hip fracture repair.
Availability and requirements
All data and related metadata underlying the findings re-
ported in this manuscript has been deposited in the de-
partment of Anesthesia in General University Hospital,
in addition provided as part of the submitted article. Au-
thors also ensure that the software will be available for a
full two years following publication, making materials, data
and associated protocols promptly available to readers
without undue qualifications.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RH conceived and designed of the study, acquired the data, performed the
statistical analysis and drafted the manuscript. JDA and IM participated in the
design and coordination of the study and revised it critically. F-JM and
LE helped to draft the manuscript. TS reviewed the study. All authors read
and approved the final manuscript.
Acknowledgments
We sincerely thank Elena García and Davinia Oltra for their contribution to
the design of randomization and the various negotiations with the Spanish
Drug Agency.
Author details
1Department of Anesthesiology, Critical Care and Pain Management,
Consorcio Hospital General Universitario (CHGUV), Valencia, Spain.
2Department of Surgery, Medical School, University of Valencia, Valencia,
Spain. 3Medical School, University of Valencia, Valencia, Spain. 4Fundación
Hospital General Universitario, Valencia, Spain. 5Department of
Anaesthesiology and Intensive Care Therapy, University Hospital
Giessen-Marburg, Faculty of Medicine, Philipps University, Marburg, Germany.
Received: 23 January 2014 Accepted: 25 September 2014
Published: 24 October 2014
References
1. González-Montalvo JI, Alarcón T, Sáez P: La intervención geriátrica puede
mejorar el curso clínico de los ancianos frágiles con fractura de cadera.
Med Clin (Barc) 2001, 116:1–5.
2. Rockwood PR, Horne JG, Cryer C: Hip fractures: a future epidemic? J Orthop
1990, 4:388–393.
3. Foss NB, Kehlet H: Mortality analysis in hip fracture patients: implications
for design of future outcome trials. Br J Anaesth 2005, 94:24–29.
4. Pages E, Cuxart A, Iborra J: Fracturas de cadera en el anciano.
Determinantes de mortalidad y capacidad de marcha. Med Clin (Barc)
1998, 110:687–691.
5. Panula J, Pihlajamaki H, Mattila VM: Mortality and cause of death in hip
fracture patients aged 65 or older: a population-based study. BMC
Musculoskelet Disord 2011, 12. http://dx.doi.org/10.1186/1471-2474-12-105.
6. Hadzic A: Textbook of regional anesthesia and acute pain management. New
York: McGraw-Hill Professional publ. comp; 2006.
7. Luger TJ, Kammerlander C, Gosch M: Neuraxial vs general anaesthesia in
geriatric patients for hip fracture surgery. Does it matter? Osteoporos Int
2010, 21(4):S555–S572.
8. Schug SA, Saunders D, Kurowski I: Neuraxial drug administration: a review of
treatment options for anaesthesia and analgesia. CNS Drugs 2006, 20:917–933.
Herrera et al. BMC Anesthesiology 2014, 14:97 Page 11 of 11
http://www.biomedcentral.com/1471-2253/14/979. Sanford M, Keating GM: Levobupivacaine. A Review of its Use in Regional
Anaesthesia and Pain Management. Drugs 2010, 70:761–791.
10. Glaser C, Marhofer P, Zimpfer G: Levobupivacaine versus racemic
bupivacaine for spinal anesthesia. Anesth Analg 2002, 94:194–198.
11. Simon MJ, Veering BT, Stienstra R: The systemic absorption and disposition of
levobupivacaine 0.5% after epidural administration in surgical patients:
a stable isotope study. Eur J Anaesthesiol 2004, 21:460–470.
12. Parker MJ, Handoll HHG, Griffiths R: Anestesia para la cirugía de fractura de
cadera en adultos (traducida de The Cochrane Library, 2008 Issue 3. Chichester,
UK: John Wiley and Sons, Ltd). E: La Biblioteca Cochrane Plus; 2008.
13. Sebastián MG, Lavanderos J, Vilches L: Fractura de cadera. Cuad Cir 2008,
22:73–81.
14. Reguant F, Bosch J, Montesinos J: Factores pronóstico de mortalidad en
los pacientes mayores con fractura de cadera. Rev Esp Anestesiol Reanim
2012, 59:289–298.
15. Fattorini F, Ricci Z, Rocco A: Levobupivacaine versus racemic bupivacaine
for spinal anaesthesia in orthopaedic major surgery. Minerva Anestesiol
2006, 72:637–644.
16. Sen H, Purtuloglu T, Sizlan A: Comparison of intrathecal hyperbaric and
isobaric levobupivacaine in urological surgery. Minerva Anestesiol 2010,
76:24–28.
17. Simon MJ, Veering BT, Stienstra R: Effect of age on the clinical profile and
systemic absorption and disposition of levobupivacaine after epidural
administration. Br J Anaesth 2004, 93:512–520.
18. Erdil F, Bulut S, Demirbilek S: The effects of intrathecal levobupivacaine
and bupivacaine in the elderly. Anaesthesia 2009, 64:942–946.
19. Wood RJ, White S: Anaesthesia for 1131 patients undergoing proximal
femoral fracture repair: a retrospective, observational study of effects on
blood pressure, fluid administration and perioperative anaemia.
Anaesthesia 2011, 66:1017–1022.
20. Minville V, Asehnoune K, Delussy A: Hypotension during surgery for
femoral neck fracture in elderly patients: effect of anaesthetic
techniques. A retrospective study. Minerva Anestesiol 2008, 74:691–696.
21. Lee YY, Muchhal K, Chan CK: Levobupivacaine versus racemic bupivacaine
in spinal anaesthesia for urological surgery. Anaesth Intensive Care 2003,
31:637–641.
22. Royal College of Physicians: National Hip Fracture Database annual report
2014. London: RCP; 2014. http://www.hqip.org.uk/assets/NCAPOP-Library/
NCAPOP-2014-15/NHFD-extended-report-2014-FINAL.pdf. (accessed 22/10/2014).
23. White SM, Moppett IK, Griffiths R: Outcome by mode of anaesthesia for
hip fracture surgery. An observational audit of 65 535 patients in a
national dataset. Anaesthesia. 2014, 69:224–230.
24. Burke D, Mackenzie M, Newton D: A comparison of vasoactivity between
levobupivacaine and bupivacaine (abstract). Br J Anaesth 1998, 81:631–632.
25. Burke D, Kennedy S, Bannister J: Spinal anesthesia with 0.5 S(-) bupivacaine
for elective lower limb surgery. Reg Anesth Pain Med 1999, 24:519–523.
26. Errando CL, Peiró CM, Gimeno A, Soriano JL: Single shot spinal anesthesia
with very low hyperbaric bupivacaine dose (3.75 mg) for hip fracture
repair surgery in the elderly. A randomized, double blinded study.
Rev Esp Anestesiol Reanim 2014, 61. doi:10.1016/j.redar.2014.02.004.
27. Olofsson C, Nygards EB, Bjersten AB: Low dose bupivacaine with sufentanil
prevents hypotension after spinal anesthesia for hip repair in elderly
patients. Acta Anaesthesiol Scand 2004, 48:1240–1244.
28. Spahn DR: Anemia and patient blood management in hip and knee surgery.
A systematic review of the literature. Anesthesiology 2010, 113:482–495.
29. Benes J, Chytra I, Altmann P: Intraoperative fluid optimization using stroke
volume variation in high risk surgical patients: results of prospective
randomized study. Crit Care 2010, 14:R118.
30. Mayer J, Boldt J, Mengistu AM: Goal-directed intraoperative therapy based on
autocalibrated arterial pressure waveform analysis reduces hospital stay in
high-risk surgical patients: a randomized, controlled trial. Crit Care 2010, 14:R18.
doi:10.1186/1471-2253-14-97
Cite this article as: Herrera et al.: Hemodynamic impact of isobaric
levobupivacaine versus hyperbaric bupivacaine for subarachnoid
anesthesia in patients aged 65 and older undergoing hip surgery.
BMC Anesthesiology 2014 14:97.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
